Advancements in gene therapy and artificial intelligence have brought the prospect of a significant extension in human lifespan closer than ever before.
Medical research aimed at enabling humans to lead longer, healthier lives in the future is currently being conducted by Harvard University researchers and biotechnology companies. What was once the domain of science fiction is now the subject of rigorous clinical trials, cutting-edge laboratory work, and serious scientific debate.
Life Biosciences, a company founded by Harvard researcher David Sinclair, has launched the first human clinical trial for ER-100—a therapy based on partial cellular reprogramming.
How ER-100 Works
In this treatment, doctors introduce genes based on “Yamanaka factors” into the eyes of patients suffering from glaucoma and nerve damage. The goal is to reset the biological age of the cells without fully converting them into stem cells—a delicate balance that could restore function without triggering uncontrolled cell growth.
Preliminary safety results are expected by late 2026 or early 2027. If successful, this trial could mark a pivotal moment in the field of regenerative medicine.
“The first person to reach the age of 150 may already be alive today, and doubling the human lifespan could become possible in the future.”
— David Sinclair, Harvard researcher and founder of Life BiosciencesHopes for “Longevity Escape Velocity” by 2035
George Church, another prominent Harvard geneticist, suggests that humanity may already be nearing the threshold of “longevity escape velocity”—a point where science becomes capable of adding more than one year of healthy life for every passing year.
If human trials for gene therapies currently in development prove successful, humanity could move beyond this stage by 2035, according to researchers. At that point, aging would no longer be a one-way street; each year of scientific progress would translate into more than a year of additional healthy life.
Artificial intelligence is also accelerating the pace of research in this field, enabling the development of safer methods for delivering genes into the body and creating improved versions of reprogramming proteins. What once took years of trial and error can now be modeled, tested, and refined in a fraction of the time.
Significant Results in Experiments on Mice
Results appear even more striking in experiments conducted on animals. One company reported that a combination of “senolytic immunotherapy” and patient-specific stem cells doubled the lifespan of aging mice while maintaining their health. Meanwhile, other research teams have extended the lifespan of mice by 30% or more using combinations of various drugs, including rapamycin and new compounds.
Aubrey de Grey’s research group has also demonstrated that combining multiple anti-aging therapies can yield better results than relying on any single treatment—a principle that may prove essential for translating these findings to humans.
New Drugs and Common Medications Also Part of Research
In a limited human trial, a drug developed with the help of artificial intelligence reduced certain biomarkers associated with biological age by three to six years. While not a dramatic change, it offers proof of concept that pharmacological interventions can influence the aging process in measurable ways.
Similarly, evidence has emerged regarding popular weight-loss drugs, suggesting they can slow the rate of biological aging markers and extend the lifespan of mice. However, researchers caution that achieving true immortality remains a distant prospect. Accidents, new diseases, and fundamental biological limitations—including DNA changes in non-dividing cells—remain significant obstacles to achieving an immortal life.
The Road Ahead
Nevertheless, rapid progress made during 2025 and 2026 has led many experts to conclude that the concept of extraordinary human life extension is no longer confined to the realm of science fiction. The combination of gene therapy, AI-driven drug discovery, and a deeper understanding of cellular biology is converging to create a new era in medicine.
While the goal of living to 150 or beyond remains speculative, the prospect of adding healthy, functional years to human life is increasingly within reach. The question is no longer whether we can intervene in the aging process, but how far those interventions will take us—and how soon.
Why it matters: Longevity research is no longer a niche scientific curiosity. It represents a fundamental shift in how we think about aging—from an inevitable decline to a biological process that can be understood, slowed, and potentially reversed. The coming decade will determine whether these breakthroughs translate into real-world benefits for human health.
Note: This article is published for informational purposes. Please follow your doctor’s advice regarding health-related matters.
